MDGL
NEUTRAL
$525.67
Live
Madrigal Pharmaceuticals, Inc. · NASDAQ
Target $668.57
(+27.2%)
$265.0
52W Range
$615.0
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 14, 2026
Market cap
$12.06B
P/E
N/A
ROE
-42.5%
Profit margin
-30.1%
Debt/Equity
0.58
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
MDGL exhibits a severe disconnect between its deterministic financial health and its growth trajectory, highlighted by a critically weak Piotroski F-Score of 1/9. While the company is experiencing explosive revenue growth of 210.80% YoY, it remains deeply unprofitable with a profit margin of -30.08% and a history of significant earnings misses. The valuation is aggressive, trading at a Price/Book of 19.92, which suggests the market is pricing in substantial future success. Despite a 'Strong Buy' analyst consensus and a high price target, heavy insider selling and a bearish technical trend suggest caution.
Key Strengths
Exceptional revenue growth (210.80% YoY)
Strong short-term liquidity with a Current Ratio of 4.01
High gross margins (94.14%) typical of successful biotech products
Strong analyst backing with a 'Strong Buy' consensus
Manageable Debt/Equity ratio of 0.58
Key Risks
Critically low Piotroski F-Score (1/9) indicating poor fundamental health
Consistent failure to meet earnings estimates (1/4 beats in last 4 quarters)
Extreme valuation premiums (P/B of 19.92 and P/S of 12.58)
Bearish insider sentiment with $18.42M in net sales and zero buys
Negative ROE (-42.49%) and ROA (-16.30%)
AI Fair Value Estimate
Based on comprehensive analysis
$580.0
+10.3% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
30
Weak
20
85
30
15
0
AI Verdict
Speculative Growth
Key drivers: Hyper-growth in revenue, Severe fundamental weakness, High valuation premium, Insider divestment
Confidence
90%
Value
20/100
Graham Number is N/A due to lack of positive earnings; stock trades at a massive premium to book value.
Positives
- Forward P/E of 41.09 is reasonable for high-growth biotech
Watchpoints
- Price/Book of 19.92 is extremely high
- Price/Sales of 12.58 indicates a steep premium
Future
85/100
Growth is the primary driver of the current stock price.
Positives
- Triple-digit revenue growth
- Strong analyst price targets ($668.57)
Watchpoints
- Unproven ability to translate revenue into consistent earnings beats
Past
30/100
Historical performance is characterized by high volatility and earnings misses.
Positives
- Strong 5-year price appreciation (+334.6%)
Watchpoints
- Poor earnings track record with an average surprise of -83.44% over the last 4 quarters
Health
15/100
Deterministic health scores are very weak, reflecting a company still in the 'burn' phase.
Positives
- High current and quick ratios indicate no immediate liquidity crisis
Watchpoints
- Piotroski F-Score of 1/9 is a major red flag
- Negative profit and operating margins
Dividend
0/100
Typical for growth-stage biotechnology firms.
Positives
No standout positives identified.
Watchpoints
- No dividend payments
- 0% payout ratio
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$525.67
Analyst Target
$668.57
Upside/Downside
+27.2%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for MDGL and closest competitors.
Updated 2026-04-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
MDGL
Madrigal Pharmaceuticals, Inc.
Primary
|
+334.6% | +119.2% | +63.1% | +22.9% | +18.2% | -1.5% |
|
ENSG
The Ensign Group, Inc.
Peer
|
+121.6% | +109.3% | +65.7% | +16.2% | -2.4% | +2.3% |
|
JAZZ
Jazz Pharmaceuticals plc
Peer
|
+19.7% | +32.4% | +90.3% | +43.4% | +4.7% | +3.9% |
|
EXEL
Exelixis, Inc.
Peer
|
+91.2% | +119.8% | +29.5% | +14.4% | +4.3% | +0.4% |
|
ALGN
Align Technology, Inc.
Peer
|
-70.6% | -48.8% | +2.3% | +24.8% | -16.9% | -5.6% |
MDG
Madrigal Pharmaceuticals, Inc.
Primary
5Y
+334.6%
3Y
+119.2%
1Y
+63.1%
6M
+22.9%
1M
+18.2%
1W
-1.5%
ENS
The Ensign Group, Inc.
Peer
5Y
+121.6%
3Y
+109.3%
1Y
+65.7%
6M
+16.2%
1M
-2.4%
1W
+2.3%
JAZ
Jazz Pharmaceuticals plc
Peer
5Y
+19.7%
3Y
+32.4%
1Y
+90.3%
6M
+43.4%
1M
+4.7%
1W
+3.9%
EXE
Exelixis, Inc.
Peer
5Y
+91.2%
3Y
+119.8%
1Y
+29.5%
6M
+14.4%
1M
+4.3%
1W
+0.4%
ALG
Align Technology, Inc.
Peer
5Y
-70.6%
3Y
-48.8%
1Y
+2.3%
6M
+24.8%
1M
-16.9%
1W
-5.6%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
41.09
PEG Ratio
N/A
P/B Ratio
19.92
P/S Ratio
12.58
EV/Revenue
11.91
EV/EBITDA
-38.23
Market Cap
$12.06B
Profitability
Profit margins and return metrics
Profit Margin
-30.08%
Operating Margin
-18.57%
Gross Margin
94.14%
ROE
-42.49%
ROA
-16.3%
Growth
Revenue and earnings growth rates
Revenue Growth
+210.8%
Earnings Growth
N/A
Q/Q Revenue Growth
+210.77%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.58
Moderate
Current Ratio
4.01
Strong
Quick Ratio
3.6
Excellent
Cash/Share
$42.88
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.3B
Gross Margin
92.4%
Op. Margin
-18.6%
Net Margin
-18.2%
Total Assets
$1.3B
Liabilities
$0.7B
Equity
$0.6B
Debt/Equity
1.09x
Operating CF
$-0.1B
Free Cash Flow
$-0.1B
FCF Yield
100%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-04-30
$N/A
2026-02-19
$-2.57
-192.2% surprise
2025-11-04
$-5.08
-104.3% surprise
2025-08-05
$-1.9
+46.2% surprise
Healthcare Sector Comparison
Comparing MDGL against 319 companies in the Healthcare sector
(20 bullish, 107 neutral, 192 bearish)
Return on Equity (ROE)
-42.49%
This Stock
vs
-86.0%
Sector Avg
-50.6%
(Below Avg)
Profit Margin
-30.08%
This Stock
vs
-11.76%
Sector Avg
+155.8%
(Superior)
Debt to Equity
0.58
This Stock
vs
3.51
Sector Avg
-83.5%
(Less Debt)
Revenue Growth
210.8%
This Stock
vs
90.15%
Sector Avg
+133.8%
(Fast Growth)
Current Ratio
4.01
This Stock
vs
3.67
Sector Avg
+9.5%
(Better)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
MDGL
Madrigal Pharmaceuticals, Inc.
|
NEUTRAL | $12.06B | - | -42.5% | -30.1% | $525.67 | |
|
ENSG
The Ensign Group, Inc.
|
NEUTRAL | $11.96B | 34.36 | 16.9% | 6.8% | $204.79 | Compare |
|
JAZZ
Jazz Pharmaceuticals plc
|
NEUTRAL | $11.96B | - | -8.5% | -8.3% | $194.2 | Compare |
|
EXEL
Exelixis, Inc.
|
BULLISH | $11.85B | 15.84 | 35.5% | 33.7% | $44.2 | Compare |
|
ALGN
Align Technology, Inc.
|
NEUTRAL | $11.78B | 29.07 | 10.4% | 10.2% | $164.23 | Compare |
MDGL
Madrigal...
NEUTRAL
Mkt Cap
$12.1B
P/E
-
ROE
-42.5%
Price
$525.67
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-06 | HUNTSMAN CAROLE A | Officer | Sale | 419 | $180,983 |
| 2026-03-06 | KELLEY SHANNON T | General Counsel | Sale | 360 | $155,498 |
| 2026-03-06 | TAUB REBECCA M.D. | Director | Sale | 491 | $212,083 |
| 2026-03-06 | SIBOLD WILLIAM JOHN | Chief Executive Officer | Sale | 1,663 | $718,316 |
| 2026-03-06 | DIER MARDI C | Chief Financial Officer | Sale | 1,982 | $853,993 |
| 2026-03-04 | HUNTSMAN CAROLE A | Officer | Stock Award | 3,989 | - |
| 2026-03-04 | KELLEY SHANNON T | General Counsel | Stock Award | 4,017 | - |
| 2026-03-04 | SIBOLD WILLIAM JOHN | Chief Executive Officer | Stock Award | 14,995 | - |
| 2026-03-04 | DIER MARDI C | Chief Financial Officer | Stock Award | 5,215 | - |
| 2026-03-04 | SOERGEL DAVID M.D. | Officer | Stock Award | 4,374 | - |
| 2026-03-02 | DIER MARDI C | Chief Financial Officer | Sale | 1,183 | $505,389 |
| 2026-02-23 | LEVY RICHARD S | Director | Option Exercise | 2,500 | $18,400 |
| 2026-01-26 | HUNTSMAN CAROLE A | Officer | Sale | 910 | $449,339 |
| 2026-01-26 | TAUB REBECCA M.D. | Director | Sale | 647 | $318,596 |
| 2026-01-26 | LEVY RICHARD S | Director | Option Exercise | 4,000 | $65,840 |
HUNTSMAN CAROLE A
Officer
2026-03-06
419 shares
·
$180,983
KELLEY SHANNON T
General Counsel
2026-03-06
360 shares
·
$155,498
TAUB REBECCA M.D.
Director
2026-03-06
491 shares
·
$212,083
SIBOLD WILLIAM JOHN
Chief Executive Officer
2026-03-06
1,663 shares
·
$718,316
DIER MARDI C
Chief Financial Officer
2026-03-06
1,982 shares
·
$853,993
HUNTSMAN CAROLE A
Officer
2026-03-04
3,989 shares
KELLEY SHANNON T
General Counsel
2026-03-04
4,017 shares
SIBOLD WILLIAM JOHN
Chief Executive Officer
2026-03-04
14,995 shares
DIER MARDI C
Chief Financial Officer
2026-03-04
5,215 shares
SOERGEL DAVID M.D.
Officer
2026-03-04
4,374 shares
DIER MARDI C
Chief Financial Officer
2026-03-02
1,183 shares
·
$505,389
LEVY RICHARD S
Director
2026-02-23
2,500 shares
·
$18,400
HUNTSMAN CAROLE A
Officer
2026-01-26
910 shares
·
$449,339
TAUB REBECCA M.D.
Director
2026-01-26
647 shares
·
$318,596
LEVY RICHARD S
Director
2026-01-26
4,000 shares
·
$65,840
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
14 analysts
B of A Securities
2026-02-20
Neutral
Neutral
Barclays
2026-01-28
Overweight
Citizens
2026-01-20
Market Outperform
Market Outperform
Piper Sandler
2025-12-19
Overweight
Overweight
B. Riley Securities
2025-12-11
Buy
Buy
HC Wainwright & Co.
2025-11-21
Buy
Buy
Oppenheimer
2025-11-20
Outperform
Outperform
Truist Securities
2025-11-19
Buy
Buy
Canaccord Genuity
2025-11-13
Buy
Buy
HC Wainwright & Co.
2025-11-11
Buy
Buy
Past News Coverage
Recent headlines mentioning MDGL from our newsroom.
Newest → oldest
No matching news yet.